Frances Mitchell Valantic
Frances Mitchell Valantič, Director of Innovation Strategy and Insight, Teleflex
Frances joined Teleflex’s global commercial team in 2021, where her focus has been on derisking and scaling new Front End Innovation processes within all global business units. Her work involves the implementation of Biodesign in the corporate setting, as well as aligning all work to the newly launched ISO56001 in Innovation Management. Her work to date has encompassed Critical Care, Benign Prostate Hyperplasia, Tracheostomy, Structural Heart, Prostate Cancer and Trauma.
Last year she developed and ran the company’s inaugural accelerator programme, modelled on Biodesign, that generated an opportunity funnel worth $1.1Bn. The accelerator included intensive immersion activities in University Hospital Galway, UNC Hospital Chapel Hill (NC) and Tower Health Reading (PA). She is currently focussed on new early business modelling and rapid indication expansion strategies.
Frances is an expert member of the NSAI/ISO working group on Innovation Management, a member of the Irish Medtech RDI working group and was previously the Chair of the Irish Medtech Commercial working group.
Prior to Teleflex, Frances was Director of Business Development for Dolmen Design and Innovation and Head of Programme Development at the UCD Innovation Academy. She worked for a number of years in the music industry as CEO of Ireland’s leading contemporary classical music ensemble, Crash Ensemble, and her first role as a graduate was in Procter & Gamble in the north of France, where she was a process engineer and line manager of 11 lines producing liquid detergent for the European market.
Frances’s academic background includes a BE in Mechanical Engineering from University College Dublin, an MPhil in Music and Media Technologies from Trinity College Dublin and an MBA from Dublin City University.